Imodium A-D

Gastroenteritis, Intestinal stoma leak, Diarrhea + 2 more
Treatment
8 FDA approvals
20 Active Studies for Imodium A-D

What is Imodium A-D

LoperamideThe Generic name of this drug
Treatment SummaryLoperamide is a long-acting medication used to treat diarrhea. It does not get absorbed into the bloodstream, so it does not affect the nervous system or the hormones that regulate blood pressure. It works by blocking the effects of histamine, which can reduce diarrhea, and it prevents the release of acetylcholine, which can also stop diarrhea.
Imodium A-Dis the brand name
Imodium A-D Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Imodium A-D
Loperamide
1989
401

Approved as Treatment by the FDA

Loperamide, otherwise called Imodium A-D, is approved by the FDA for 8 uses including Inflammatory Bowel Diseases (IBD) and Diarrhea .
Inflammatory Bowel Diseases (IBD)
Diarrhea
Traveler's Diarrhea
Gastroenteritis
Intestinal stoma leak
Diarrhea
Chronic Functional Diarrhea
Crohn's Disease

Effectiveness

How Imodium A-D Affects PatientsLoperamide is a medication used to treat diarrhea. It works by slowing down the movement of food through the digestive tract, allowing more water and electrolytes to be absorbed from the intestines. It also increases rectal tone, reducing fecal volume and making the stool firmer. It usually takes about an hour for it to start working and can last for up to three days. Although loperamide is an opioid, it does not produce pain relief at typical doses. However, very high doses can allow it to pass into the brain, where it can cause opioid effects and toxicity. In extreme cases, loperamide
How Imodium A-D works in the bodyLoperamide works by binding to opioid receptors on intestinal muscles. This causes a chain reaction that reduces nerve activity in the intestines and decreases the release of certain chemicals that cause muscle contractions. As a result, loperamide slows movement in the intestines, allowing more water and electrolytes to be absorbed. It also reduces the amount of muscle contractions, making stools harder and drier.

When to interrupt dosage

The advised dosage of Imodium A-D is contingent upon the determined disorder, including Diarrhea, Crohn's Disease and Ulcerative Colitis, as well as Intestinal stoma leakage. The extent of dosage depends on the technique of delivery, as exemplified in the table below.
Condition
Dosage
Administration
Gastroenteritis
, 2.0 mg, 1.0 mg/mL, 0.2 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Suspension, Suspension - Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Kit - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Intestinal stoma leak
, 2.0 mg, 1.0 mg/mL, 0.2 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Suspension, Suspension - Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Kit - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Diarrhea
, 2.0 mg, 1.0 mg/mL, 0.2 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Suspension, Suspension - Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Kit - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Crohn's Disease
, 2.0 mg, 1.0 mg/mL, 0.2 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Suspension, Suspension - Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Kit - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Chronic Functional Diarrhea
, 2.0 mg, 1.0 mg/mL, 0.2 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Suspension, Suspension - Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Kit - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Imodium A-D Contraindications
Condition
Risk Level
Notes
Abdominal Pain
Do Not Combine
Therapeutic procedure
Do Not Combine
Pulse Frequency
Do Not Combine
Dysentery
Do Not Combine
Enterocolitis
Do Not Combine
Ulcerative Colitis
Do Not Combine
There are 20 known major drug interactions with Imodium A-D.
Common Imodium A-D Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Loperamide.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Loperamide.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Loperamide.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Loperamide.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Loperamide.
Imodium A-D Toxicity & Overdose RiskTaking more than the recommended dose of loperamide can be very dangerous and may lead to life-threatening heart issues such as abnormal heart rhythms, fainting, cardiac arrest, and even death. Loperamide overdoses can also cause confusion, sleepiness, decreased coordination, pinpoint pupils, muscle stiffness, slowed breathing, low blood pressure, difficulty urinating, and a blocked intestine. Naloxone can be used to reverse the opioid-related effects of an overdose.
image of a doctor in a lab doing drug, clinical research

Imodium A-D Novel Uses: Which Conditions Have a Clinical Trial Featuring Imodium A-D?

Investigation is currently underway to investigate the potential of Imodium A-D to ameliorate Chronic Functional Diarrhea, Intestinal stoma leakage and Gastroenteritis.
Condition
Clinical Trials
Trial Phases
Diarrhea
0 Actively Recruiting
Crohn's Disease
26 Actively Recruiting
Phase 1, Not Applicable, Early Phase 1, Phase 2, Phase 4
Chronic Functional Diarrhea
0 Actively Recruiting
Intestinal stoma leak
0 Actively Recruiting
Gastroenteritis
12 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1

Imodium A-D Reviews: What are patients saying about Imodium A-D?

5Patient Review
1/30/2016
Imodium A-D for Diarrhea
Immodium A-D always does the trick for me when I need it. It's quick, painless, and easy with no real side effects that I've noticed.
5Patient Review
3/2/2018
Imodium A-D for Diarrhea
This treatment always works perfectly for me.
4.3Patient Review
5/18/2017
Imodium A-D for Diarrhea
Imodium AD helps to slow down my bowel motility and as a result, I'm not as worried about sudden onsets of diarrhea. It's not perfect, but it allows me to go out and do the things I need to do.
3.7Patient Review
4/29/2010
Imodium A-D for Diarrhea
I experienced diarrhea after taking the drug Plaquenil, which was effective in other ways. However, it caused such severe dehydration that I suffered from double vision a few times before quitting the medication entirely.
3.7Patient Review
5/20/2009
Imodium A-D for Diarrhea
I take a lot of this medication, and it still doesn't completely relieve my symptoms. I experience severe cramping and bloating, with pain from my belly button to my vaginal cavity. However, without the drug I couldn't function at all. If anyone has any suggestions, please let me know.
3.7Patient Review
5/15/2016
Imodium A-D for Diarrhea
This medication was effective at stopping my diarrhea. However, I have now been constipated for the last three days. So, it seems I've traded one problem for another.
3.7Patient Review
1/23/2008
Imodium A-D for Diarrhea due to Inflammatory Bowel Disease
I developed blood in my stool after starting this medication.
3.7Patient Review
7/21/2014
Imodium A-D for Diarrhea
At first, this medication worked great. But a few hours later I started having intense pain in my upper abdomen, gas and bad bloating.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about imodium a-d

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When do you take Imodium A-D?

"At first, adults should take 4 milligrams (mg) of loperamide after the first loose bowel movement. After the first dose, they should then take 2 mg of loperamide after each loose bowel movement. The doctor may adjust the dose as needed, but the usual dose is not more than 16 mg (8 capsules) per day."

Answered by AI

What does AD stand for in Imodium?

"There are two forms of Imodium available, one with just the active drug loperamide, and the other with loperamide and simethicone. Both forms are available as a generic drug."

Answered by AI

What is difference between Imodium and Imodium A-D?

"Loperamide is a medication used to treat diarrhea, while Imodium Multi-Symptom Relief can be used to treat diarrhea, bloating, cramps, and pressure caused by gas. Both medications are available over the counter."

Answered by AI

What does Imodium A-D do for you?

"This medication is used to treat sudden diarrhea. It works by slowing down the movement of the gut, which decreases the number of bowel movements and makes the stool less watery."

Answered by AI

Clinical Trials for Imodium A-D

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA
While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.
Phase < 1
Waitlist Available
Stanford Digestive Health Clinic (+1 Sites)Sean P Spencer, MD, PhD
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Image of Atlanta VA Medical and Rehab Center, Decatur, GA in Decatur, United States.

Measurement-Based Care for Inflammatory Bowel Disease

18+
All Sexes
Decatur, GA
This research study is addressing issues related to Inflammatory bowel disease (IBD), which is a chronic autoimmune disorder that affects over 60,000 Veterans. With close monitoring and timely treatment adjustment, the investigators can stop the natural progression of IBD, improving health-related quality of life (HRQOL) and reducing flares and hospitalizations. However, it is difficult to closely monitor Veterans with IBD between clinic visits. There is a critical need for solutions that support close between visit monitoring of Veterans with IBD. The Measurement-Based Care (MBC) for IBD study will take a systematic approach to collect, share, and act on patient reported outcome (PRO) data that can be used to achieve close monitoring. MBC supports patients' in managing their condition and boosting their confidence in their ability to handle their symptoms and disease, and also supports care teams in early recognition of health issues. The investigators will work with both Veterans and their care teams to understand and assess this program so it can be a model for future initiatives.
Waitlist Available
Has No Placebo
Atlanta VA Medical and Rehab Center, Decatur, GA (+3 Sites)Shirley Cohen-Mekelburg, MD MS
Have you considered Imodium A-D clinical trials? We made a collection of clinical trials featuring Imodium A-D, we think they might fit your search criteria.Go to Trials
Image of Victoria Hospital - London Health Sciences Centre in London, Canada.

Vitamin D for Inflammatory Bowel Disease

18 - 85
All Sexes
London, Canada
The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period? 2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients? 3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period? 4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period? 5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients? 6. Is 2,000 IU/Day an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients? Participants will: * Take 2000 IU of Vitamin D every day for the next 12 months * Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up
Phase 1
Waitlist Available
Victoria Hospital - London Health Sciences CentreTerry Ponich, MD
Image of Massachusetts General Hospital in Boston, United States.

Diet and Stress Management for Inflammatory Bowel Disease

18+
All Sexes
Boston, MA
Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, immune-mediated disease characterized by recurrent episodes of relapse. The goal of this single site, pragmatic, randomized trial is to answer if combining lifestyle modifications (mindfulness/stress management + nutrition support) with advanced therapies for induction and maintenance of clinical remission in CD and UC as evaluated by disease activity scores in patients with active CD and UC. Researchers will compare 4 study arms (Group 1, Group 2, Group 3, and Group 4) to see if combining lifestyle modifications with advanced therapies for induction and maintenance will show improvement in condition as evaluated by disease activity scores. Groups: 1. Group A - Subjects will receive a visit with an IBD dietician and a visit with an IBD GI psychologist within the first month of advanced therapy initiation and another visit with both parties 4+/-2 weeks after the first intervention visit. 2. Group B - Subjects will receive a visit with an IBD dietician within the first month of advanced therapy initiation and another visit 4+/-2 weeks after the first intervention visit. They will later be offered a visit with an IBD GI psychologist after 3 months (after assessment of our primary outcomes). 3. Group C - Subjects will receive a visit with an IBD psychologist within the first month of advanced therapy initiation and another visit with the IBD GI psychologist 4+/-2 weeks after the first intervention visit. They will later be offered a visit with an IBD dietician after 2 months (after assessment of our primary outcomes). 4. Group D - Subjects will be offered a visit with an IBD GI psychologist and IBD dietician after 3 months (after assessment of our primary outcomes). All subjects will be asked to complete a set of questionnaires and have the option to give blood and stool samples throughout the life of their participation in the study at certain visits.
Recruiting
Has No Placebo
Massachusetts General HospitalAshwin Ananthakrishnan, MD, MPH
Have you considered Imodium A-D clinical trials? We made a collection of clinical trials featuring Imodium A-D, we think they might fit your search criteria.Go to Trials
Image of University of Texas at Arlington in Arlington, United States.

Confocal Laser Endomicroscopy for IBD

2 - 21
All Sexes
Arlington, TX
This study aims to test the overall hypothesis that the membrane tissue binding capacity of cytokines in the biopsied tissue of patients with Inflammatory Bowel Disease (IBD) is predictive of/strongly correlated to clinical response/outcomes observed. The key questions under investigation are: Aim 1: To assess the fluorescent signal intensity at baseline (control antibody with control biopsy and control antibody with IBD biopsy). Aim 2: To characterize the cellular landscape by surveying surface markers using bar-coded antibodies and performing gene expression profiling on every cell within inflamed tissue of patients with IBD. Aim 3: Develop algorithm using artificial intelligence to predict responders versus non-responders and to further subclassify IBD patients using phenotype data.
Waitlist Available
Has No Placebo
University of Texas at Arlington (+1 Sites)Clifton Huang, MD
Image of Toronto Immune and Digestive Health Institute in North York, Canada.

Healing Circuits™ for Inflammatory Bowel Disease

18 - 75
All Sexes
North York, Canada
The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the online self-directed curriculum will be receiving the therapy mostly by web-based video instruction. The two groups will be evaluated over a period of 12 months.
Recruiting
Has No Placebo
Toronto Immune and Digestive Health InstituteMarci Reiss, DSWAmgen
Have you considered Imodium A-D clinical trials? We made a collection of clinical trials featuring Imodium A-D, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security